Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Pancreatic Cancer
  •  Radiation Therapy
  •  Blood Cancer
  •  Immunology
  •  Radiation Oncology
  •  Haemato-Oncology
  •  Colorectal Cancer
  •  Hematology


Citation: Clin Oncol. 2021;6(1):1874.DOI: 10.25107/2474-1663.1874

NLRP3 Inflammasome Enhances Tumor Growth

Bernhard Ryffel

Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, Orleans, France

*Correspondance to: Bernhard Ryffel 

 PDF  Full Text Mini Review | Open Access


Tumor cell derived danger signals known as DAMPs activate the NLRP3 inflammasome leading to IL-1β/IL-18 production conferring a pro-inflammatory environment. The inflammatory tumor environment enhances the tumor progression and metastasis. The NLRP3 inflammasome or IL-1/IL-18 represents promising therapeutic targets in cancer therapy, which is discussed in this
review. Alternative targets such TLRs and cGAS/STING dependent immune regulators need to be considered. The metabolome and microbiome of the host are additional factors contributing to a successful chemo- and immunotherapy.


Cite the Article:

Ryffel B. NLRP3 Inflammasome Enhances Tumor Growth. Clin Oncol. 2021;6:1874..

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

PEGylation of AS16 Double-Target Peptide that Blocks the Neuropilin-1 and Tie2 Signaling Pathways Enhances its Antitumor Effect
 Abstract  PDF  Full Text
CEA and CA19-9 Levels and KRAS Mutation Status as Biomarkers for Colorectal Cancer
 Abstract  PDF  Full Text
View More...